Q3 2024 AxoGen Inc Earnings Call Transcript
Key Points
- Axogen Inc (AXGN) reported a strong third quarter with revenue growth of approximately 18% year-over-year, reaching $48.6 million.
- The company achieved an adjusted EBITDA of $6.5 million, a significant increase from $2.4 million in the previous year.
- Axogen Inc (AXGN) completed the rolling submission process for the Biologic License Application (BLA) for its advanced nerve graft, with the FDA accepting the filing for substantive review.
- The company saw broad-based growth across its portfolio, including increased nerve reconstruction cases and adoption of new solutions like the AAG HA nerve protector and Avive Plus soft tissue matrix.
- Axogen Inc (AXGN) maintained its full-year revenue guidance and expects to be at the high end of its gross margin guidance, reflecting confidence in its financial performance.
- Despite strong third-quarter performance, Axogen Inc (AXGN) chose not to adjust its full-year guidance, which some analysts viewed as conservative.
- The company's gross margin decreased to 74.9% from 76.8% in the same period last year, attributed to product mix changes.
- Operating expenses increased by 2.9% year-over-year, driven by higher general and administrative costs, including stock-based compensation.
- The company reported a net loss of $1.9 million for the quarter, although this was an improvement from the previous year's loss.
- Potential risks include supply chain disruptions, as mentioned in the context of hurricane impacts, which could affect revenue.
Good morning, everyone. Joining me on today's call is Michael Dale Axogen's Chief Executive Officer and Director Anir Naor, Chief Financial Officer, Michael will discuss third quarter, 2024 financial results and Nir will provide an analysis of our financial performance and guidance and discuss our outlook for the year followed by a question-and-answer session.
Today's call is being broadcast live via webcast which is available on the investors section of Axogen's website. Following the end of the live call, a replay will be available in the investors section of the company's website at www dot axogeninc dotcom.
Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements, forward-looking statements include but are not limited to all statements relating to financial guidance including revenue margins, cash flow and future profitability.
The availability to fund ongoing operations, the availability to expand markets and revenue expectations for growth, marketing opportunities within existing and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
